Washington, District of Columbia 20060

  • Drug Dependence


STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

Study summary:

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.


Inclusion Criteria: 1. HIV+, confirmed by rapid HIV test 2. Meet DSM-IV criteria for opioid dependence 3. 18 years or older 4. Have health insurance that is accepted at Lab Corp. Exclusion Criteria: 1. Are <18 years old; 2. Are HIV negative; 3. Are Unable to communicate in English; 4. Are not able to provide informed consent; 5. Do not meet DSM-IV criteria for opioid dependence; 6. Plan to leave the DC area



Primary Contact:

Principal Investigator
Fredrick Altice, MD
Yale University School of Medicine/AIDS Program

Backup Contact:


Location Contact:

Washington, District of Columbia 20060
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.